Amoeboid durotaxis may not be propelled by differential actin flow.
(A) Actin flow speed of dHL-60 cells adhered on different substrate stiffness (4 kPa, 40 kPa, 75 kPa, 120 kPa and 160 kPa). Each plot indicated the average actin flow speed of every individual cell adhered on polyacrylamide gel. All error bars are SEM. *, P < 0.05, ****, P < 0.0001, by One-way ANOVA.
(B) Actin flow speed of softer side and stiffer side of the dHL-60 cells adhered on gradient substrate. Each plot indicated the average actin flow speed of softer or stiffer part of a cell adhered on stiffness gradient gel. All error bars are SEM. ns, not significant, by Student’s t-test.
(C) Actin flow speed of control (DMSO) and CK-666 (100 μM, pre-treated for 5 h) treated CD4+ Naïve T cells moving on stiffness gradient gel (n = 20 tracks were analyzed for each experiment, N = 3 independent experiments for each condition, replicates are biological). All error bars are SEM. ****, P < 0.0001, by Student’s t-test.
(D) y-FMI of control (DMSO) and CK-666 (100 μM, pre-treated for 5 h) treated CD4+ Naïve T cells moving on stiffness gradient gel (n ≥ 30 tracks were analyzed for each experiment, N = 3 independent experiments for each condition, replicates are biological). All error bars are SEM. ns, not significant, by Student’s t-test.
(E) y-FMI, velocity and migration persistence of control (DMSO), nocodazole (Noco, 32 μM, pre-treated for 10 min) treated and taxol (70 nM, pre-treated for 10 min) treated CD4+ Naïve T cells moving on stiffness gradient gel (n ≥ 30 tracks were analyzed for each experiment, N = 3 independent experiments for each condition, replicates are biological). All error bars are SEM. ns, not significant, by One-way ANOVA.
(F) y-FMI, velocity and migration persistence of control (DMSO), blebbistatin (Bleb, 10 μM, pre-treated for 10 min) treated and Rho activator II (Rho, 0.25 μg/ml, pre-treated for 2 h) treated CD4+ Naïve T cells moving on stiffness gradient gel (n ≥ 30 tracks were analyzed for each experiment, N = 3 independent experiments for each condition, replicates are biological). All error bars are SEM. ***, P < 0.001, ****, P < 0.0001, ns, not significant, by One-way ANOVA. All drugs were incubated for the whole experiment.
(G) y-FMI, velocity and migration persistence of control (DMSO), blebbistatin (Bleb, 10 μM, pre-treated for 10 min) treated and Rho activator II (Rho, 0.25 μg/ml, pre-treated for 2 h) treated neutrophils moving on stiffness gradient gel (n ≥ 30 tracks were analyzed for each experiment, N = 3 independent experiments for each condition, replicates are biological). All error bars are SEM. *, P < 0.05, ****, P < 0.0001, ns, not significant, by One-way ANOVA. All drugs were incubated for the whole experiment.
(H) y-FMI, velocity and migration persistence of control (DMSO), blebbistatin (Bleb, 10 μM, pre-treated for 10 min) treated and Rho activator II (Rho, 0.25 μg/ml, pre-treated for 2 h) treated dHL-60 cells moving on stiffness gradient gel (n ≥ 30 tracks were analyzed for each experiment, N = 3 independent experiments for each condition, replicates are biological). All error bars are SEM. ****, P < 0.0001, ns, not significant by One-way ANOVA.